Real-world data on GLP-1R agonists’ safety in heart failure and CKD patients was investigated using the TriNetX Research ...
The impact of GLP-1 RAs on alcohol use is explored, showing potential benefits in reducing intake and cravings, but with ...
A recent study found that glucagon-like peptide-1 receptor (GLP-1) agonists like semaglutide and liraglutide are effective in ...
Glucagon-like peptide-1 receptor (GLP-1) agonists, particularly semaglutide, could be effective in reducing alcohol-related ...
Based on the review, the researchers promote the integration of GLP-1 receptor agonists as a primary treatment for obesity in ...
News Medical on MSN1d
GLP-1 drugs, like semaglutide, lower risk of hospitalizations for alcohol use disorderFindings suggest semaglutide and other GLP-1 agonists may significantly reduce alcohol use disorder hospitalizations, ...
Medpage Today on MSN3d
Tirzepatide Officially Puts GLP-1 Meds on the Map for Obesity-Related Heart FailureA long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and accompanying ...
In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community ...
GLP-1 drug shortages, driven by cosmetic and weight loss purposes, result in access disparities among individuals with ...
Medpage Today on MSN6d
GLP-1 Drugs Could Help People With Alcohol Use DisorderSome GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...
Dr, Garner said, "Glucagon-like peptide-1 (GLP-1) receptor agonists represent a significant advancement in the treatment of ...
Apollo Therapeutics Group Ltd. and Sunshine Lake Pharma Co. Ltd. inked a potential $938 million licensing deal for APL-18881 (HEC-88473), Sunshine’s dual fibroblast growth factor 21 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback